# Safety and Efficacy of VDPHL01 in Males With AGA

> **NCT06972264** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Veradermics, Inc.** · enrollment: 480 (estimated)

## Conditions studied

- Androgenetic Alopecia
- AGA
- Male Pattern Baldness

## Interventions

- **DRUG:** VDPHL01
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06972264
- **Lead sponsor:** Veradermics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-11
- **Primary completion:** 2026-12
- **Final completion:** 2027-07
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06972264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06972264, "Safety and Efficacy of VDPHL01 in Males With AGA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06972264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*